spacer
home > pmps > autumn 2017 > supervising substances
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Supervising Substances

Since its conception in 2006, the Registration, Evaluation, Authorisation and restriction of CHemicals (REACH) regulation has had a significant impact on the chemical industry in the EU. The primary purpose of this legislation is to gain more knowledge about chemical substances so that companies can better protect their employees and the environment and inform the public about potential substance hazards.

While the intentions of REACH are clear and simple, in reality, this legislation is complicated and difficult to implement for many companies. The European Chemicals Agency (ECHA) has tried to help by publishing several detailed guidelines, but sometimes the explanations and examples caused more confusion. Substances that have to be registered by the 2018 deadline lie in the 1-100 tonne tonnages. Companies have to prepare registration dossiers for each substance, which contain substance information, such as toxicological and ecotoxicological tests, physicochemical properties, guidance for safe use and more. This is a big problem that manufacturers or importers have to face, as many of them have minimum information about their substances, and, because of REACH, they have to spend large sums of money on obtaining this information.

However, most pharmaceutical companies have the opportunity to register their substances as transported or isolated intermediates. According to REACH, on on-site isolated intermediate is defined as a substance, which is used for the manufacture of another substance, and takes place on the same site, whereas a transported isolated intermediate is moved between or supplied to other sites. Registering as an intermediate is a big advantage because the amount of information needed for the registration dossier and associated costs are significantly decreased. To be able to register these substances as intermediates, they have to be handled under strictly controlled conditions, which must be well-founded and documented. In the end, the simplified registration is not as simple as expected.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Jana Osičková works as an officer in the department of Ecology and Emergency Prevention at Farmak – a traditional European generic API manufacturer in the Czech Republic. She graduated from Brno University of Technology, Czech Republic, with a master’s degree in food science and biotechnology. She is a specialist in REACH legislation and SCCs and is currently working on registering substances used and manufactured in Farmak. 
spacer
Jana Osičková
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Cheshire Business Awards 2018: Technoprint Cheshire Ltd. wins Corporate Social Responsibility Award

Technoprint has prided itself on being a socially responsible organisation since it was founded in 1988. Winning the Corporate Social Responsibility award is a real testament to their ethos and shows that hard work and making a difference to the local area really does make an impact in the long term, internally and externally.
More info >>

White Papers

pAVEway™ expression system for the efficient expression of therapeutic proteins

Fujifilm Diosynth Biotechnologies

One of the major bottlenecks in the production of biopharmaceuticals is the efficient expression of therapeutic proteins in microbial or mammalian cells. The Escherichia coli pAVEway™ expression system described here has been developed to ensure high product titres and efficient scale up to GMP manufacture, whilst minimising many common issues seen in other expression systems, such as ‘leaky’ expression (expression of recombinant protein in the absence of inducer).
More info >>

 
Industry Events

Drug Delivery Partnerships 2019

28-30 January 2019, PGA National Resort & Spa in Palm Beach Gardens, FL

For 23 years, DDP has been the world’s largest drug delivery meeting place to accelerate drugs to market and lengthen lifecycles for long term profitability by finding new partners, new drug delivery technologies, and new formulation development strategies. Year after year this event brings together top scientists and business development leaders from Biotech, Pharma, Generics, Specialty Pharma and Drug Delivery companies to share, discuss, and collaborate. If you work in drug delivery, commercialization/licensing, med device, formulation, biologics, biosimilars, and similar areas, you can’t miss this event!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement